Oman Pharmaceutical Import: A 2026 Guide for UK Exporters and Oman Buyers

The Sultanate of Oman is a steady and well organised pharmaceutical market within the Gulf. Its public hospital network, run by the Ministry of Health alongside the Royal Hospital, the Sultan Qaboos University Hospital, and a growing private sector, depends on imported finished medicines for a large share of supply. For UK exporters of UK-licensed, MHRA-authorised medicines, Oman is an attractive destination: the regulatory framework recognises medicines approved by stringent authorities such as the MHRA, the documentation expectations map cleanly onto the UK quality system, and the named patient route gives hospitals a practical way to access UK-licensed products that are not yet registered locally.

This guide is written for hospital and Ministry of Health procurement teams, licensed Oman distributors, and UK suppliers who need a clear, accurate view of how a UK-licensed medicine reaches an Omani hospital pharmacy in 2026. It covers the regulator and its role, the registration and import-permit pathway, the documents typically required, how UK-licensed supply fits the framework, the named patient import route as the buyer's in-country mechanism, cold chain and Good Distribution Practice expectations, and the common pitfalls that delay shipments.

A note on scope before we begin. Euro Biom is a UK MHRA-licensed wholesale exporter. We supply UK-licensed, finished, MHRA-authorised medicines. We are not a manufacturer, a pharmacy, or a regulatory consultancy, and the regulatory facts below are described in general terms drawn from the Oman Ministry of Health framework. Confirm specific fees, timelines, and current forms with the DGPA&DC or your Oman registered agent before relying on them.

The Regulator: Oman Ministry of Health and the DGPA&DC

Pharmaceutical regulation in Oman sits with the Ministry of Health, exercised through the Directorate General of Pharmaceutical Affairs and Drug Control, commonly abbreviated to DGPA&DC. This directorate is the national competent authority for medicines. Its remit covers the registration of pharmaceutical products, the granting of marketing authorisations, the control of pharmaceutical pricing, the licensing of pharmaceutical establishments, and pharmacovigilance and drug safety surveillance. The Drug Safety Center, which sits within this structure, administers practical services including applications to import non-registered medicines.

The governing principle is straightforward. Every medicine intended for sale or hospital use in Oman, whether locally manufactured or imported, must hold a marketing authorisation from the DGPA&DC before it can be commercialised. That marketing authorisation is granted product by product, is valid for five years, and is renewable. Around this central registration requirement sit the defined exceptions, most importantly the unregistered and named patient import route, which exist precisely because no national registration system can keep pace with the full range of specialty and rare disease medicines that hospitals occasionally need.

For UK exporters, the most important feature of the Oman framework is that it gives explicit weight to prior approval by recognised stringent regulators. A medicine that already holds a UK MHRA marketing authorisation, or approval from the US FDA or Western European authorities, is treated more favourably, both in full registration and, in particular, when an institution applies to import an unregistered product on a named patient basis.

The Registration and Import-Permit Pathway

There are two layers to bringing a medicine into Oman: registering the product, and obtaining permission to import each consignment. Understanding how they relate avoids a great deal of wasted effort.

Product registration (marketing authorisation)

Full registration is the route for any product that will be supplied routinely and at scale. The application is built around a CTD or eCTD dossier and submitted to the DGPA&DC by a locally licensed agent on behalf of the foreign manufacturer or marketing authorisation holder. The dossier is validated, then assessed for quality, safety, and efficacy, with the Technical Committee for Registration and Pharmacovigilance taking the final decision. Where the reviewers raise deficiencies, the applicant is given a defined window to respond, and each cycle adds time. On approval, the product receives a five-year renewable marketing authorisation. Pricing is reviewed as part of registration, with Oman commonly comparing the proposed price against reference prices in other markets.

Import permits and licences

Registration establishes that a product may be sold in Oman. Separately, each physical consignment generally requires an import permit or licence obtained by the licensed agent or distributor. For bulk medicines destined for public hospital use, importation is undertaken under tender award and requires an import licence. For unregistered medicines accessed through the named patient route, the Drug Safety Center issues a specific authorisation tied to the defined clinical need rather than a standing registration.

The local agent requirement

A recurring feature across all of these routes is the local agent. Oman's foreign investment framework generally requires a foreign company that wishes to do business in the Sultanate to operate through a locally established entity. In the pharmaceutical context, that means a foreign manufacturer or marketing authorisation holder must appoint a locally licensed agent or distributor. The agent submits the registration dossier, applies for import permits, manages variations and renewals, and acts as the regulatory point of contact. A UK wholesale exporter does not replace the Oman agent; it operates the UK supply leg and coordinates the documentation that the agent then files.

Documents Typically Required

The Oman dossier follows the GCC and ICH Common Technical Document structure, with country-specific supplements. The exact requirements depend on whether the product is going through full registration or an unregistered import, but the core documents for a UK-sourced product are well established.

Two documents deserve particular attention for UK suppliers. The first is the Certificate of Pharmaceutical Product. The MHRA issues CPPs in WHO format through its Export Certificate service, and Oman expects a current certificate naming the manufacturing site and the approved product information. CPP turnaround should be built into any project plan early, because a registration deadline is fixed but certificate issuance is not instant. The second is the free-sale certificate from the country of origin, which Oman has historically expected to cover a defined period of free sale in the UK. Our standalone resource on the UK pharmaceutical import documentation set explains how these certificates are assembled on the UK side.

Documents originating in the UK generally need to be legalised so that they are accepted by the Omani authorities. In practice this means notarisation and attestation, typically through the relevant UK channels and the Omani diplomatic mission, alongside chamber attestation of commercial documents such as the invoice and packing list. Confirm the exact legalisation chain with your agent, as attestation requirements are periodically updated.

How UK-Licensed Supply Fits the Framework

The Oman framework is well suited to UK-licensed finished medicines, and it is worth being precise about why. Euro Biom supplies medicines that already hold a UK marketing authorisation and are MHRA-authorised finished products. That status carries three practical advantages into Oman.

• Recognised regulatory provenance. Oman gives explicit weight to medicines approved by stringent authorities including the MHRA. A UK marketing authorisation, evidenced by the MHRA CPP, is exactly the country-of-origin assurance the Oman system is built to recognise.
• Clean documentation mapping. The MHRA CPP, GMP certificate, free-sale certificate, Qualified Person batch release, and Certificate of Analysis are the same documents the Oman dossier and import applications call for. There is no translation gap between the UK quality system and the Omani expectation.
• Traceable supply chain. Supplying through an MHRA Wholesale Dealer Authorisation, with Good Distribution Practice from a UK warehouse to despatch, gives the Oman buyer an auditable chain of custody for a finished, licensed product.

This is the right place to be clear about positioning. Euro Biom supplies UK-licensed, finished, MHRA-authorised medicines only. We do not supply unlicensed specials, and the named patient route described next is not a way for us to supply an unlicensed product. It is the buyer's in-country regulatory mechanism for importing a product that holds a UK marketing authorisation but is not yet registered in Oman.

The Named Patient Route as the Buyer's Import Mechanism

No registration system covers every medicine a hospital might need. Oman addresses this with a defined provision: in exceptional circumstances, an unregistered medicine may be imported where there is a specific clinical demand to treat a category of patients and no suitable registered alternative exists in the local market. In practice this functions as a named patient import route.

The key features for a buyer to understand are these. The application is made by the prescribing institution or its licensed agent, not by the UK supplier. It is tied to a defined clinical need and a defined quantity, for identified patients, rather than to open-ended commercial supply. The Drug Safety Center authorises the import on that basis. And, importantly for UK exporters, importation is generally made easier where the product is already approved by a recognised authority such as the MHRA, the FDA, or Western European regulators, and where it is prescribed for rare or exceptional conditions.

For a UK-licensed product, this is precisely the buyer's route to a finished medicine that holds a UK marketing authorisation but has not yet completed Oman registration. The Omani hospital pharmacy or its agent submits the import application and clinical justification; Euro Biom supplies the UK-licensed finished product together with the country-of-origin certificate, batch documentation, and Certificate of Analysis that support it. The two halves fit together: the in-country regulatory permission, and the UK quality-assured supply. Our named patient supply page sets out the UK-side process in detail, and the wider service map is on the services page.

Cold Chain and Good Distribution Practice

A meaningful share of UK pharmaceutical exports to Oman are temperature-sensitive, including specialty oncology lines and other 2 to 8 degree Celsius products. Oman, like its Gulf neighbours, expects temperature integrity to be maintained and evidenced across the journey, and the elevated ground temperatures in Muscat and across the interior make this non-negotiable rather than a formality.

The core expectations a UK supplier should meet are:

• Validated temperature-controlled storage in MHRA-validated facilities at the specified range, typically 2 to 8 degrees Celsius for cold chain products.
• Qualified shipping containers validated for the ambient profile of the Heathrow to Muscat route, including summer ground temperatures at destination.
• Continuous temperature monitoring with a calibrated data logger accompanying the consignment from packing to acceptance, with the logger record available for inspection on arrival.
• Stability data covering the transit profile, which for most MHRA-approved cold chain products is already supported by the existing dossier.
• A Good Distribution Practice compliant chain from the UK warehouse, through Heathrow cargo handling, to Muscat International Airport, and onward to the agent or hospital.

Heathrow to Muscat is well served by direct flights, making same-day despatch achievable for urgent consignments, with delivery into the destination hospital typically within a couple of days including arrival checks. For the practical mechanics, see our UK cold chain pharmaceutical supply page.

Common Pitfalls

Most delays in Oman supply trace back to a small number of avoidable issues. Each is straightforward to manage with the right preparation.

1. Out-of-date or wrong-format CPP

Oman expects a current MHRA CPP in WHO format naming the manufacturing site. Internal export certificates that are not in WHO format, or a certificate that has aged out, are a frequent cause of resubmission. Request the CPP from the MHRA well ahead of the intended filing window.

2. Missing or short free-sale certificate

The free-sale certificate from the country of origin is a recurring requirement, historically expected to cover a defined period of free sale in the UK. Confirm the current period with your agent and obtain the certificate early.

3. Incomplete legalisation chain

UK documents usually need notarisation and attestation through the appropriate channels before they are accepted in Oman. Starting legalisation late, or missing a step in the chain, can hold an otherwise complete file at the border.

4. Treating registration and import permit as one step

Registration permits sale; the import permit or licence authorises the consignment. Bulk public hospital supply additionally runs through tender and an import licence. Mapping which permission applies to your route at the outset prevents avoidable surprises.

5. Cold chain excursion handling

Even with validated shipping, occasional excursions occur. Without a deviation review procedure agreed with the consignee in advance, an excursion can quarantine a consignment while the parties negotiate handling. Agree the procedure in the supply contract.

6. Underusing the named patient route

Buyers sometimes assume that an unregistered UK-licensed medicine is simply unavailable. In many cases the named patient import route provides a compliant path for defined patients, particularly given Oman's favourable treatment of MHRA-approved products. Raising it early can unlock supply that would otherwise stall.

How Euro Biom Supports Oman Supply

Euro Biom is a UK MHRA-licensed pharmaceutical wholesale exporter, holding Wholesale Dealer Authorisation WDA(H) 59239. We supply UK-licensed, finished, MHRA-authorised medicines, and we operate the UK supply leg of a compliant export into Oman, working alongside manufacturers, marketing authorisation holders, licensed Oman agents, and hospital procurement teams.

Across the Oman pathway, our role typically covers:

• UK-side documentation, including coordinating MHRA Certificate of Pharmaceutical Product and free-sale certificate procurement with the manufacturer or MA holder, GMP certificate retrieval, and the export pack of CoA, batch release, packing list, and chamber-attested commercial invoice.
• Cold chain logistics from Heathrow, with GDP-validated temperature-controlled storage, qualified shipping containers, calibrated data loggers, and direct routing to Muscat International Airport.
• Named patient supply, providing the UK-licensed finished product and supporting documentation so the Omani hospital pharmacy or its agent can file the import application for identified patients.
• Tender support, supplying the finished UK-licensed product and documentation packs to the Oman distributor or agent holding a Ministry of Health tender award.
• Shortage supply, rapid response where Heathrow proximity, MHRA-licensed inventory, and same-day despatch are decisive.

For the country landing page, see UK pharmaceutical exporter to Oman. To compare Oman against other Gulf and regional regulators side by side, use our regulator comparison tool. The UK-side documentation set is detailed on the UK pharmaceutical import documentation page.